Table 4.
Promising COVID-19 inactivated vaccines (IV) and live-attenuated vaccine (LAV) candidates in clinical development.
| Type | Manufacturer | Name | Phase | RoA | Trial Registration |
|---|---|---|---|---|---|
| IV | Sinovac | CoronaVac | Approved (China, Indonesia) | IM | NCT04756830 |
| IV | Sinopharm | SARS-CoV-2 vaccine | Phase 3 | IM | ChiCTR2000034780 |
| IV | Sinopharm | BBIBP-CorV | Approved (China, Bahrain, UAE) | IM | NCT04863638 |
| IV | Institute of Medical Biology + Chinese Academy of Medical Sciences | SARS-CoV-2 vaccine | Phase 3 | IM | NCT04659239 |
| IV | Research Institute for Biological Safety Problem (Kazakhstan) | QazCovid-in® | Phase 3 | IM | NCT04691908 |
| IV | Bharat Biotech | COVAXIN® | EUA (India) | IM | NCT04641481; CTRI/2020/11/028976 |
| IV | Beijing Minhai Biotechnology | Inactivated SARS-CoV-2 vaccine | Phase 3 | IM | NCT04852705 |
| IV | Valneva, National Institute for Health Research, United Kingdom | VLA2001 | Phase 3 | IM | NCT04864561 |
| LAV | Codagenix/Serum Institute of India | COVI-VAC | Phase 1 | IN | NCT04619628 |
| LAV | Meissa Vaccines | MV-014-212 | Phase 1 | IN | NCT04798001 |
RoA, route of administration; IM, Intramuscular; IN, Intranasal.